GlassScriptPhysician profile
Gary Pearson Ozier
NPI 1922086065
$3,569.18
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $1,325 · 2021: $960.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.70 | 2019-2021 | |
| Lilly USA, LLC | $600.89 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $445.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $286.80 | 2019-2021 | |
| Amarin Pharma, INC. | $262.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $241.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $196.41 | 2019-2021 | |
| Astellas Pharma US INC | $107.73 | 2020 | |
| Pfizer INC. | $96.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.95 | 2019-2021 | |
| Philips North America LLC | $38.00 | 2019 | |
| Amgen INC. | $34.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $30.17 | 2019-2021 | |
| Allergan, INC. | $27.26 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.88 | 2021 | |
| Lundbeck LLC | $19.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.18 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.38 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.85 | 2019 | |
| Genentech USA, INC. | $11.54 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$875.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ozier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.